<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
INBX
Inhibrx
$
()


  • Inhibrx files to sell 2.45M shares of common stock for holders

    6/11/2024 - 17:16pm
  • Largest borrow rate increases among liquid names

    5/31/2024 - 08:45am
  • Sanofi completes acquisition of Inhibrx

    5/30/2024 - 09:07am
  • Inhibrx stockholder approve sale to Sanofi

    5/24/2024 - 16:03pm
  • Inhibrx just downgraded at Jefferies, here's why

    2/28/2024 - 19:39pm
  • Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)

    2/28/2024 - 09:17am
  • Inhibrx just downgraded at LifeSci Capital, here's why

    1/23/2024 - 16:18pm
  • Inhibrx to sell INBRX-101 to Sanofi in $2.2B transaction

    1/23/2024 - 05:31am
  • Inhibrx just downgraded at JMP Securities, here's why

    1/23/2024 - 04:26am
  • Inhibrx reports Q3 EPS ($1.10), consensus ($1.01)

    11/9/2023 - 16:02pm
  • Inhibrx reports preliminary Phase 1 efficacy and safety data in Ewing sarcoma

    11/2/2023 - 09:18am
  • Inhibrx announces Chiesi Farmaceutici declined option for rights on INBRX-101

    9/19/2023 - 16:02pm
  • Inhibrx sells 3.62M shares at $19.35 in private placement

    8/29/2023 - 09:02am
  • Inhibrx price target lowered to $27 from $35 at JMP Securities

    8/23/2023 - 06:03am
  • Inhibrx reports Q2 EPS ($1.08), consensus ($1.03)

    8/7/2023 - 16:02pm
dynamic_feed Breaking News